Differentiating TYK2 inhibitors with real-world evidence in psoriasis

A pharmaceutical manufacturer used real-world evidence to shape launch strategy for an oral TYK2 inhibitor in psoriasis. The analysis identified "topical-to-systemic patients most ready to advance" by studying the growth pathway established by apremilast, revealing untapped market-expansion opportunity, and found "NPs and PAs as high-value targets in community dermatology," prompting a reshaped field-force targeting plan. The study also examined free drug program dynamics, treatment discontinuation, and prescriber behavior to inform differentiated pre-launch positioning. No specific numerical outcomes are given on the landing page.

The customer is anonymised in HealthVerity’s own case study — not withheld by us.

HealthVerity is a real-world-data marketplace aggregating claims, EHR and lab data from 75+ sources via a proprietary patient-matching layer.

This sits in the Data Providers stage of the AI use-case lifecycle: Named examples from the real-world-data, claims and competitive-intelligence providers pharma AI systems are trained on, benchmarked against, or run inside of.